Hello Fintel Support Team,
I’m currently monitoring CERo Therapeutics Holdings, Inc. (Ticker: CERO) on Fintel, and I noticed that the “Short Shares Availability” for US-CERO has dropped to zero as of October 30, 2025 (UTC).
I would like to confirm the following points urgently, as the stock is reportedly being delisted from Nasdaq today (October 31, 2025, U.S. time):
- Is the short share availability of "0" caused by full utilization of lendable shares, or due to a broker-side restriction related to the delisting and upcoming OTC transition?
- Once trading is suspended on Nasdaq, will Fintel continue to update short interest, borrow fee rate, and short volume data for CERO (if it moves to the OTC market)?
- Is there any recent data or update on the Short Squeeze Score or Market Maker assignment for CERO?
- Does Fintel expect that CERO will still have any tradeable volume after delisting, or will data coverage end completely?
The situation seems highly time-sensitive, so I would appreciate your clarification at your earliest convenience.
Thank you for your assistance.
Best regards,